Drug Profile
Montelukast nanoparticle - PharmaKing
Alternative Names: MKT-N2; PMK-M01RS1Latest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator PharmaKing
- Class Acetates; Anti-inflammatories; Antiasthmatics; Antidementias; Bronchodilators; Neuroprotectants; Nootropics; Quinolines; Small molecules
- Mechanism of Action Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Asthma
- Discontinued Allergic rhinitis
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for phase-I development in Asthma in South Korea (PO, Liposomal)
- 17 May 2016 Chemical structure information added
- 12 May 2016 Discontinued - Phase-I for Allergic rhinitis (In volunteers) in South Korea (PO)